The U.S. market for both generalized and localized anesthesia drugs is expected to grow nearly four percent to be worth $7 billion by 2015, according to a MedReps report.
Drug companies that manufacture ketamine are expected to lead profits in the category, according to an Anesthesia Drug Market study. Ketalar, distributed by JHP Pharmaceuticals, is currently the only branded version of the drug offered on the market.
Ketalar is expected to maintain a high profile in the market over the next five years, according to the study, but could see a drop in sales due to an increasing demand for less expensive generic counterparts.
Anesthesiologist Receives American Pain Society Award
Anesthesiologist Elected to Massachusetts Medical Society House of Delegates
Drug companies that manufacture ketamine are expected to lead profits in the category, according to an Anesthesia Drug Market study. Ketalar, distributed by JHP Pharmaceuticals, is currently the only branded version of the drug offered on the market.
Ketalar is expected to maintain a high profile in the market over the next five years, according to the study, but could see a drop in sales due to an increasing demand for less expensive generic counterparts.
Related Articles on Anesthesiology:
Two Anesthesiologists Selected to Lead St. Joseph Medical Center Anesthesia DepartmentAnesthesiologist Receives American Pain Society Award
Anesthesiologist Elected to Massachusetts Medical Society House of Delegates